Tri Locum Partners LP Cassava Sciences Inc Call Options Transaction History

Tri Locum Partners LP

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q4 2022 Feb 14, 2023	SELL	$27.82 - $44.16 $4.51 Million - $7.16 Million	-162,100 Reduced 56.03%	127,200 $3.76 Million
Q3 2022 Nov 14, 2022	BUY	$16.33 - $51.06 $4.72 Million - $14.8 Million	289,300 New	289,300 $12.1 Million

196

13.8M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.